Compound Global Advisors LLC Purchases Shares of 3,703 HCA Healthcare, Inc. (NYSE:HCA)

Compound Global Advisors LLC purchased a new position in shares of HCA Healthcare, Inc. (NYSE:HCA) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 3,703 shares of the company’s stock, valued at approximately $1,111,000. HCA Healthcare accounts for 4.5% of Compound Global Advisors LLC’s investment portfolio, making the stock its 8th biggest holding.

A number of other hedge funds have also modified their holdings of the stock. Legacy Investment Solutions LLC bought a new stake in HCA Healthcare during the 3rd quarter worth approximately $39,000. Activest Wealth Management raised its holdings in shares of HCA Healthcare by 1,250.0% in the fourth quarter. Activest Wealth Management now owns 135 shares of the company’s stock valued at $40,000 after buying an additional 125 shares during the last quarter. Canoe Financial LP bought a new position in shares of HCA Healthcare in the third quarter worth about $41,000. Capital Performance Advisors LLP acquired a new stake in shares of HCA Healthcare in the third quarter valued at approximately $41,000. Finally, Northwest Investment Counselors LLC bought a new position in HCA Healthcare in the third quarter valued at about $44,000. 62.73% of the stock is owned by institutional investors and hedge funds.

HCA Healthcare Stock Down 1.2 %

NYSE:HCA opened at $318.28 on Tuesday. The firm’s 50 day simple moving average is $313.75 and its 200 day simple moving average is $353.51. The company has a market cap of $80.62 billion, a PE ratio of 14.49, a P/E/G ratio of 1.11 and a beta of 1.64. HCA Healthcare, Inc. has a one year low of $289.98 and a one year high of $417.14. The company has a debt-to-equity ratio of 69.07, a current ratio of 1.08 and a quick ratio of 0.97.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings results on Friday, January 24th. The company reported $6.22 EPS for the quarter, beating analysts’ consensus estimates of $6.03 by $0.19. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. During the same period last year, the firm posted $5.90 EPS. On average, research analysts anticipate that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 17th will be given a dividend of $0.72 per share. This is a positive change from HCA Healthcare’s previous quarterly dividend of $0.66. The ex-dividend date is Monday, March 17th. This represents a $2.88 annualized dividend and a dividend yield of 0.90%. HCA Healthcare’s dividend payout ratio is presently 12.02%.

Insider Buying and Selling at HCA Healthcare

In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of the firm’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the sale, the insider now directly owns 6,843 shares in the company, valued at approximately $2,415,579. This trade represents a 29.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Phillip G. Billington sold 3,897 shares of the firm’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $350.00, for a total value of $1,363,950.00. Following the completion of the sale, the senior vice president now owns 52,702 shares of the company’s stock, valued at approximately $18,445,700. This represents a 6.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

HCA has been the topic of a number of analyst reports. TD Cowen cut their price target on HCA Healthcare from $450.00 to $440.00 and set a “buy” rating on the stock in a research note on Monday, October 28th. KeyCorp reduced their price objective on HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating for the company in a research report on Tuesday, January 7th. Wells Fargo & Company cut HCA Healthcare from an “equal weight” rating to an “underweight” rating and decreased their price objective for the company from $400.00 to $320.00 in a report on Monday, November 25th. Barclays lowered their price objective on shares of HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $405.00 price target on shares of HCA Healthcare in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $385.67.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.